Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Non-comparative Screening Trial of Sacituzumab Tirumotecan (MK2870) Alone and in Combination With Pembrolizumab in Ovarian Clear Cell Carcinoma Previously Exposed to Immunotherapy

NCT07718854 is registered in ClinicalTrials.gov with Tufts Medical Center as lead sponsor.

NCT NCT07718854
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07718854 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Non-comparative Screening Trial of Sacituzumab Tirumotecan (MK2870) Alone and in Combination With Pembrolizumab in Ovarian Clear Cell Carcinoma Previously Exposed to Immunotherapy
Lead sponsor
Tufts Medical Center
Phase
Phase 2
Overall status
Recruiting
Start date
September 30, 2026
Completion date
September 30, 2036
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic ovarian cancer, ovarian clear cell carcinoma, recurrent ovarian clear cell adenocarcinoma